ITMCTR2100005045
Recruiting
Phase 4
Clinical study on the treatment of myocardial remodeling after acute myocardial infarction by integrated traditional Chinese and western medicine
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Qilu Hospital of Shandong University
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Aged 30 to 75 years;
- •2\. Emergency admission STEMI patients who meet the 4th edition of the global definition of AMI (cTnI peak value \> 99% upper limit of the reference value (URL) and have an ascending and descending curve, and have clinical evidence of myocardial ischemia.
- •3\. All patients have received emergency PCI, and the infarct\-related arterial TIMI blood flow classification has reached grade 3, within 10 days after PCI;
- •4\. Voluntarily participate in this study and have signed the informed consent.
Exclusion Criteria
- •1\. AMI combined with severe acute heart failure uncontrolled;
- •2\. AMI combined with cardiogenic shock (Killip grade \>\= grade III), who did not respond to vasopressors;
- •3\. AMI complicated with severe arrhythmia (sustained ventricular tachycardia, ventricular fibrillation), second\-degree or higher atrioventricular block, and rapid atrial fibrillation;
- •4\. AMI complicated with mechanical complications (ventricular septal perforation, papillary muscle rupture, cardiac thrombus, ventricular free wall rupture);
- •5\. Severe systemic diseases (severe infection, massive hemorrhage due to anticoagulation and antithrombotics, respiratory failure);
- •6\. History of cerebral hemorrhage and cerebral aneurysm within 3 months;
- •7\. Severe hepatic and renal insufficiency \[ALT \>\= 3 ULN (Upper Limit of Normal), Cr \> 134µmol/L (2mg/dl) or eGFR \< 45ml/min/1\.73m2].
- •8\. Patients with neuropsychiatric diseases;
- •9\. Malignant tumor;
- •10\. Other pathophysiological states with expected survival less than 1 year;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Treatment of cardiac amyloid light-chain amyloidosis with the green tea compound epigallocatechin-3-galiateAmyloid light-chain amyloidosisNutritional, Metabolic, EndocrineAmyloidosisISRCTN68399350Ruprecht-Karls-University of Heidelberg (Germany)38
Not yet recruiting
Phase 1
Clinical trial on the safety of myocardium regenerative therapy for ischemic heart disease using biodegradable polymeric carrier and basic fibroblast growth factorIschemic heart diseaseJPRN-UMIN000018709Kyoto University Graduate School of Medicine Department of Cardiovascular Surgery5
Recruiting
Not Applicable
Clinical trial on the treatment of coronary microvascular disease with Shexiang Tongxin dropping pillcoronary microvascular diseaseITMCTR2024000027Guangdong provincial Hospital of Chinese Medicine
Not yet recruiting
Phase 2
A cohort study on the treatment of coronary heart disease with the method of promoting qi and blood circulation (retrospective)Coronary heart diseaseITMCTR2023000063Xiyuan Hospital, China Academy of Chinese Medical Sciences
Not yet recruiting
Not Applicable
A cohort study on the treatment of coronary heart disease with the method of promoting qi and blood circulation (prospective)Coronary heart diseaseITMCTR2023000064Xiyuan Hospital, China Academy of Chinese Medical Sciences